tbuckley/cabot-search huggingface dataset:
AB0124 EFFECTS OF INHIBITOR K-CARRAGEENAN ON HAECs INFLAMMATORY RESPONSE TO LDLs ISOLATED FROM SLE PATIENTS
Authors: S. Parra, A. Avila, J. Rivalta, M. Guardiola, R. Rodriguez, A. Castro
Journal: Annals of the Rheumatic Diseases (2022)

Background Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a high risk of atherosclerosis and cardiovascular events. It was previously reported by our group that low-density lipoprotein (LDL) particles isolated from SLE patients, during an active state of the disease (‘flare’), promoted an exaggerated inflammatory response in human aortic endothelial cells (HAECs). However, the molecular mechanisms underlying this response still remain elusive. Objectives The hypothesis of this study is that these SLE-LDLs would be using receptor LOX-1, associated with inflammatory conditions and altered lipoproteins, to generate the proatherogenic response in HAECs. Methods LOX-1 pharmacological inhibitor k-carrageenan was used before the stimulation of HAECs with LDLs isolated from healthy controls (10), non-active (13), or active-SLE patients (13). Gene expression, protein, and cell migration assays were performed to evaluate HAECs inflammatory response. Results LOX-1 inhibition with k-carrageenan significantly reduced the expression of vascular cell adhesion molecule 1 (VCAM-1) and restored the gene expression of endothelial nitric oxide synthase (eNOS) in HAECs incubated with non-active SLE LDLs. Conclusion While VCAM-1 down-regulation was expected, the immediate next step derived from the observed results will be a deeper understanding of how LOX-1 inhibition may restore the endothelial ability to synthetize NO in the presence of altered LDL. This will allow gaining insight not only on the development of atherosclerosis but also on the clue mechanisms involved in the pathogenesis of SLE. Disclosure of Interests None declared
AB0607 Vascular involvement in Behçet’s Disease
Authors: I. Chaabene, S. Tahri, M. Kechida, S. Daada, S. Hammami, R. Klii, I. Khochtali
Journal: Annals of the Rheumatic Diseases (2022)

Background Behçet’s disease (BD) is a multisystemic inflammatory vasculitis, which can affect all types and sizes of blood vessels. It diagnosis is based on a multitude of classification criteria, which include vascular complications associated to this vasculitis. Objectives In this study, we reported the main characteristics of vascular involvement in patients with BD. Methods In total, 243 patients with BD were, retrospectively, collected in the Internal Medicine Department over 18 years. Results Vascular involvement was present in 72 patients (29.6%), whose 57 men and 15 women. The mean age was 32.9 years (range: 5-56 years). It revealed the disease in 26.3% of cases. Venous involvement was predominant, found in 68% of patients. Venous thrombosis interested: the upper limbs (51%), the lower limbs (38.7%), the pulmonary veins (18.3%), the inferior vena cava (12.2%) and the cerebral veins in 1 patient. Superficial venous thrombosis was present in 20.8% of cases. Arterial involvement was present in 11.1% of patients. It included pulmonary artery aneurysms in 8 cases and occlusion of the central retinal artery in one patient. The other associated systemic manifestations were: skin and mucous membrane disorders (100%), joint involvement (34.7%), ocular (29.2%), neurological (27.8%) and cardiac involvement in 7 patients. Treatment was based on long term curative anticoagulation (70%), corticosteroid therapy (50%) and immunosuppressive treatment in 21% of cases. Embolization was performed in two patients with good results. Conclusion Our study illustrates the frequency and the polymorphism of vascular involvement in BD. References [1]Kechrid Laouani C; Rev Med Int 2021; 42: A360 Disclosure of Interests None declared
AB0446 IMPROVEMENT OF BELIMUMAB ON QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: G. Yi, S. Zheng, X. Guo, M. Liu, T. Li
Journal: Annals of the Rheumatic Diseases (2022)

Background Accumulating evidence supports an impaired quality of life in patients with systemic lupus erythematosus (SLE). A study reported the patients concerns centred on fatigue [1] . Objectives We investigated the effect of belimumab on quality of life in patients with SLE. Methods SLE patients from Guangdong Second Provincial General Hospital treated with belimumab (n=19) or control group (n=22) were included. Patients in control group were in traditional treatment without belimumab. Data were collected prospectively at treatment initiation and now, including Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Pittsburgh Sleep Quality Index (PSQI) and the SF-36 (Table 1). Table 1. SLEDAI P PSQI P SF-36 P Group Pre-treatment Post-treatment - Pre-treatment Post-treatment - Pre-treatment Post-treatment - Belimumab group 11±4.67 6.11±3.55 0.001 6±3.83 3.58±2.01 0.02 519.47±187.79 685.62±141.78 0.004 Control group 8.82±5.69 3.55±2.11 0.000 6.5±3.52 5.86±3.24 0.536 541.73±185.22 700.42±123.90 0.002 P 0.199 0.007 - 0.665 0.011 - 0.705 0.723 - Results Belimumab group showed improvement in SLEDAI, PSQI and the SF-36 (P＜0.05). Control group was improvement in SLEDAI and the SF-36 (P＜0.05), no changes in PSQI (P=0.536). However, the improvement of belimumab group in SLEDAI and PSQI observably outperformed the improvement of control group. Conclusion Belimumab effectively improve quality of life in patients with SLE. Further study of pediatric patients with SLE is still warranted. References [1]Golder V, Ooi J, Antony A S, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus,2018,27(3):501-506. Disclosure of Interests None declared
POS1540-HPR CENTRAL SENSITIZATION PLAYS A PROMINENT ROLE IN DISEASE ACTIVITY, FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE IN PATIENTS WITH SPONDYLOARTHRITIS.
Authors: A. Ben Tekaya, C. Ines, A. Gharbi, O. Saidane, R. Leila, S. Bouden, R. Tekaya, I. Mahmoud, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2022)

Background Pain in rheumatic diseases is substantially due to an excess of nociception in response to chronic inflammation. However, the share of nociplastic pain in these disorders shouldn’t be overlooked. Different tests have been evaluated but some of them require expensive equipment. Objectives to assess The Central Sensitization in young patients with spondyloarthritis (SpA) using a simple and validated tool: The Central Sensitization Inventory (CSI). Methods We conducted a cross-sectional study including patients with SpA, fulfilling the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria. For all patients, we collected the following data: age, age at onset of SpA, disease duration, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing spondylitis quality of life score (ASQOL) and functional statement by Bath ankylosing spondylitis functional index (BASFI). Nociceptive pain was assessed by VAS pain, neuropathic pain was assessed by DN4 and nociplastic pain was assessed by CSI. Univariable and multivariable linear regression analyses were used to investigate the association between CSI scores, patient-related parameters and disease characteristics. Results Sixteen SpA patients (50 axial SpA, 8 axial and peripheral SpA, 1 psoriatic arthritis and 1 SpA associated with inflammatory bowel disease) were enrolled. There were 22 females and 38 males. Mean age was 39,4 years ± 11,08, mean age at onset was 23,61 years± 8,5 and mean disease duration was 11,37 years ±7,23. Mean night awakenings was 0,92 [0, 3], mean VAS pain was 5,27 [1, 9]. Mean BASDAI was 3,53 ± 3,34, mean BASFI was 4,01 ± 2,53, mean ASQOL was 6,3 ± 5,128 and mean DN4 was 1,72 [0, 7]. Mean CSI score was 20,38 ± 18,657. Six patients (10%) had a CSI score≥ 40, which indicates a central sensitization. CSI score&gt;40 was not associated with the gender (p=0,659), nor axial presentation of SpA (p=0,644), nor the presence of coxitis (p=0,217). CSI score was not correlated with disease duration (p=0,306) nor age at onset (p=0,376). It was however associated with a BASDAI&gt;4 (p=0,039). A positive correlation was found between higher CSI score and higher ASQOL (p&lt;0,001, r=0,744), VAS pain (p=0,061, r=0,282), more frequent night awakenings (p=0,009, r=0,433), higher BASDAI (p=0,006, r=0,379) and higher BASFI (p=0,055, r=0,270). Conclusion Higher CSI score was associated with higher disease activity, more frequent night awakenings, poorer quality of life and greater functional impairment. A global and comprehensive management including these factors as well as nociplastic pain should help the patient achieve better outcomes. Disclosure of Interests None declared
AB0304 CHRONIC KIDNEY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY
Authors: M. J. Mantilla Ribero, J. C. Sarmiento Monroy, C. Villota-Eraso, D. C. Varela, J. C. Hurtado, M. Rodriguez-Jimenez, R. D. Mantilla Hernández
Journal: Annals of the Rheumatic Diseases (2022)

Background Prevalence and incidence estimates for chronic kidney disease (CKD) in rheumatoid arthritis (RA) vary and it may result from comorbidities, chronic inflammation, aging, or effects of drugs used for the disease. Objectives To calculate the prevalence and incidence of CKD in a cohort of patients with RA. Methods This was a retrospective cohort study in which well-characterized patients with RA (fulfillment of 1987 ACR criteria) were included from 2014 to 2021. Patients were evaluated at a single rheumatology outpatient center in Bogotá, Colombia. Baseline and follow-up estimated glomerular filtration rate (eGFR) were calculated according to CKD-EPI equation. CKD was defined as an eGFR &lt;60 mL/min/1.73 m2. Results A total of 783 outpatients were included. Baseline characteristics were as follows: female gender 81.6%, mean age 51.8±11 years, mean disease duration 8 (IQR 3-15) years, RF positive 80.1%, ACPA positive 58.2%, and erosions 24.9%. Most patients have received glucocorticoids (89.8%), and conventional synthetic DMARDs (97.8%), being prednisone and methotrexate the most frequently prescribed. Hypertension was the most frequent comorbidity (27.7%). CKD was found in 43 (5.5%) patients at the time of inclusion, being hypertension the most common cause (24, 55.8%). Only 12 (1.5%) patients had a documented history of CKD at the beginning of the follow-up. The median of follow-up was 73 months. Fifteen incident cases of CKD were found (15/358, 4.1%) in patients with follow-up data of at least 1 year and without prior CKD. Main characteristics of the patients are shown in Table 1. Table 1. Cardiovascular disease and main comorbidities in RA patients. Baseline (n/783 ) Prevalent CKD (n/43 ) Incident CKD (n/15 ) Cardiovascular Disease n (%) n (%) n (%) Hypertension 217 (27,7) 24 (56) 6 (40) Coronary artery disease 27 (3,4) 3 (7) 2 (13) Thrombosis 14 (1,8) 2 (5) 2 (13) Stroke 11 (1,4) 1 (2) - Chronic occlusive arterial disease 4 (0.5) 1 (2) 1 (7) Comorbidity n (%) n (%) n (%) Dyslipidemia 209 (26,7) 16 (37) 9 (60) Diabetes mellitus type 2 55 (7) 3 (7) - Conclusion There is an underestimation of the prevalence of CKD in patients with RA in routine clinical practice due to the absence of a systematic estimation of eGFR. The incidence of CKD is low in the Colombian population. References [1]Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63(2):206-13. [2]Couderc M, Tatar Z, Pereira B, Tiple A, Gilson M, Fautrel B, et al. Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-Sectional Multicenter Study. Arthritis Care Res (Hoboken). 2016;68(5):638-44. Disclosure of Interests None declared
AB1079 INFECTIOUS SACROILIITIS ACCORDING TO THE GERM: ABOUT 42 CASES
Authors: S. Rekik, S. Boussaid, H. Tbini, S. Jemmali, S. Rahmouni, K. Zouaoui, H. Sahli, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2022)

Background Infectious sacroiliitis is a rare rheumatological emergency. Its semiology is misleading due to the deep location of the joint. The responsible germs play an important role in its semiology. Objectives The objective of this work was to identify the germs responsible for infectious sacroiliitis and their effect in the sacroiliac joint. Methods We conducted a retrospective study, including 42 patients hospitalized for infectious sacroiliitis over a period from 2000 to 2020. Demographic, clinical, biological and radiographic data were collected. Results A total of 42 Patients were enrolled (11 men and 31 women). The mean age was 36,7 years [29-76]. Low back pain with difficulty walking were the most common manifestations (88%). The inflammatory syndrome was present in 70% of cases. Standard radiographs showed loss of cortical margins with erosion of the sacroiliac joints in 34 cases and were normal for the rest of the patients. MRI and CT scan were performed to confirm the diagnosis in 28 and 13 cases respectively. A puncture guided by ultrasound or scanner was performed in 24 patients. In the cases of absence of germ on the conventional examinations, we performed a sacroiliac biopsy and histological examinations. Pyogenic germs were responsible for 46% of infectious sacroiliitis: Staphylococcus Aureus in 11 cases (28%), Escherichia Coli in 7 cases (16 %) and Streptococcus in one case (2%). Tuberculosis and Brucella were responsible for 38% and 7% of the cases respectively. A subcutaneous abscess was associated with tuberculous sacroiliitis in 4 patients. The outcome was favorable in 36 cases (86%) under appropriate antibiotic therapy. Eight patients presented a treatment-related complication. Progression to multifocal bone tuberculosis and chronic brucellosis was noted in one case each. In 3 cases, rapid ankylosis was found on radiological control. Unfortunately, one patient died from septic shock. Conclusion Common germs are most responsible for infectious sacroiliitis and seem to have the best prognosis. Tuberculosis is responsible for various complications and its treatment has a high iatrogenic risk. Chronicity is the most feared development, mainly during Brucella sacroiliitis and would be related to a loss of antibiotic efficacy. Disclosure of Interests None declared
POS1448 DICKKOPF HOMOLOG 3 (DKK3) AS A PROGNOSTIC MARKER IN LUPUS NEPHRITIS: A PROSPECTIVE MONOCENTRIC EXPERIENCE
Authors: S. Sciascia, M. Radin, A. Barinotti, I. Cecchi, D. Rossi, R. Fenoglio, D. Roccatello
Journal: Annals of the Rheumatic Diseases (2022)

Background Lupus nephritis (LN) is a major cause of mortality/morbidity in patients affected by systemic lupus erythematosus (SLE). Reliable prognostic markers, especially related to the degree of interstitial fibrosis, are still lacking and renal biopsy still represents the gold standard. Recent data suggests a role of Dickkopf homolog 3 (DKK3) as a marker of tissue fibrosis in different diseases, however its role in autoimmune diseases still needs to be elucidated. Objectives To investigate DKK3 serum levels in SLE patients with and without LN, assessing its changes in relation to kidney function, flares and interstitial renal fibrosis, as well as its association with the IFN signature. Methods 132 SLE patients, 57 of whom diagnosed with LN, were included in this study, as well as 50 healthy donors. DKK3 and Myxovirus resistance protein 1 (MxA) were measured in serum samples, using enzyme-linked immunosorbent assays. Biopsies were evaluated for glomerular involvement, interstitial renal fibrosis and tubular atrophy according to 2003 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification and the revised 2018 version. Patients were followed-up for at least 36 months. Results DKK3 serum levels were significantly higher in patients with biopsy-proven LN when compared to those without (median[min-max]: 215ng/ml [81-341] vs 21.1ng/ml [1-69], p&lt;0.01). When focusing on patients with LN, DKK3 levels resulted to be associated with the presence of chronic kidney disease (OR: 4.31[C.I. 2.01-6.61] per DKK3 doubling, p&lt;0.01), higher chronicity index at biopsy (OR: 1.75[C.I. 1.59-2.13] per DKK3 doubling, p&lt;0.01) and flares rate (OR: 1.45[C.I. 1.1-5.71] per DKK3 doubling, p&lt;0.044). DKK3 levels correlated with the IFN signature as expressed by MxA (correlation coefficient: 0.71, p&lt;0.037). Conclusion While kidney biopsy remains the gold standard for diagnostic and prognostic assessment in LN, DKK3 could represent an additional useful prognostic tool to monitor SLE patients and eventually to guide therapeutic choices. Disclosure of Interests None declared
POS0402 CLONALLY EXPANDED CD38hi CYTOTOXIC CD8 T CELLS DEFINE THE T CELL INFILTRATE IN CHECKPOINT INHIBITOR-ASSOCIATED ARTHRITIS
Authors: R. Wang, A. Singaraju, K. E. Marks, L. Shakib, G. Dunlap, A. Cunningham-Bussel, S. R. Greisen, L. Chen, A. Tirpack, M. Fein, D. Todd, L. Macfarlane, S. Goodman, E. Dicarlo, E. Massarotti, J. Sparks, O. P. Hamnvik, L. Min, A. H. Jonsson, M. Brenner, K. K. Chan, A. Bass, L. Donlin, D. Rao
Journal: Annals of the Rheumatic Diseases (2022)

Background Immune checkpoint inhibitor (ICI) therapies that promote T cell activation have improved outcomes for advanced malignancies yet can also elicit harmful autoimmune reactions. The T cell mechanisms mediating these iatrogenic autoimmune events remain unclear. Objectives To investigate the immunophenotype, transcriptomic feature and clonotypes of T cells from joints of patients affected by ICI-induced inflammatory arthritis (ICI-arthritis). Methods Detailed immunophenotyping was performed on mononuclear cells from synovial fluid (SF) using mass cytometry and flow cytometry to identify significantly altered populations in ICI-A compared to seropositive rhrumatoid arthritis (RA) and psoriatic arthritis (PsA) (p&lt;0.05). Bulk RNA-seq was performed on altered SF CD8 T cell subsets from ICI-A, RA and PsA to investigate their transcriptomic features. Cytokine profile and pathways enriched in ICI-A CD8 T cells were examined using differentially expressed genes, intracellular staining, and in vitro culture. TCR clonotypes were examined using single cell RNA-seq of T cells from synovial fluid, tissue and blood of ICI-A. Results Compared to the autoimmune arthritides RA and PsA, ICI-arthritis joints contained an expanded CD38 hi CD127 - CD8 + T cell subset that displays cytotoxic, effector, and interferon (IFN) response signatures. Exposure of synovial T cells to Type I IFN, more so than IFN- γ , induced the CD38 hi cytotoxic phenotype. Single cell transcriptomic and T cell repertoire (TCR) analyses indicated that the abundance of CD38 hi CD8 T cells in ICI-arthritis resulted from proliferation of a limited number of clones. The CD38 hi population appeared distinct from dysfunctional T cells and clonally most related to TCF7 + memory populations. Comparison of synovial tissue from bilateral knees of the same patient demonstrated considerable sharing of TCR clonotypes among CD38 hi CD8 T cells between the two joints. Further, TCR clonotypes expanded in synovial fluid of ICI-arthritis patients were detected in circulating T cells, and circulating CD38 hi CD8 T cells are also expanded in ICI-arthritis patients. Conclusion These results define a distinct CD8 T cell subset in the synovial fluid and in the circulation of patients with ICI-A that may be directly activated by ICI therapy to mediate a tissue-specific autoimmune response. Disclosure of Interests None declared.
AB0460 METABOLOMIC PROFILE OF INSULIN RESISTANCE IN NON-DIABETIC WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: P. Munguía-Realpozo, C. Mendoza Pinto, I. Etchegaray-Morales, S. K. Vélez-Pelcastre, Á. D. Osorio-Peña, S. Méndez-Martínez, M. A. Escamilla-Márquez, M. García Carrasco
Journal: Annals of the Rheumatic Diseases (2022)

Background Systemic lupus erythematosus (SLE) is associated with an increased risk of insulin resistance (IR). Metabolomics offers an opportunity to examine markers of IR and their relationship with SLE. Objectives 1) to compare the metabolomic profile of IR in SLE patients and controls; 2) to correlate the metabolomic profile with other IR surrogates and 3) to evaluate the relationship between the metabolomic profile of IR and SLE disease variables, vitamin levels and subclinical atherosclerosis in patients with SLE. Methods In this cross-sectional analysis, serum samples were collected from patients with SLE (n= 64) and gender- and age-matched controls (n= 71). Serum metabolomic profiling was performed using ultra-high performance liquid chromatography and tandem mass spectrometry (UPLC-MS-MS). Homeostasis model assessment (HOMA) and the quantitative insulin sensitivity check index (QUICKI) were also carried out. Serum 25(OH)D concentrations were assessed by chemiluminescent immunoassay. Carotid IMT was quantified by ultrasound. Results In non-diabetic patients with SLE, the metabolomic Quantose score significantly moderately correlated with HOMA-IR, HOMA2-IR and QUICKI. Although levels of IR metabolites did not differ between SLE patients and controls, fasting plasma insulin levels were higher and insulin sensitivity lower in SLE patients. The Quantose IR score was significantly correlated with complement C3 levels (r= 0.7; p= 0.001). Neither 25 (OH)D nor IMT was correlated with any metabolite or Quantose IR index. Conclusion This exploratory study found that Quantose IR may be a useful tool for IR assessment. There was a possible correlation between the metabolomic profile and complement C3 levels. The implementation of this metabolic strategy may help develop biochemical insight into metabolic disorders in SLE. References [1]Yan B, Huang J, Zhang C, Hu X, Gao M, Shi A, et al. Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS. Modern Rheumatology 2016;26:914–22. doi:10.3109/14397595.2016.1158895. [2]Gu X, Al Dubayee M, Alshahrani A, Masood A, Benabdelkamel H, Zahra M, et al. Distinctive Metabolomics Patterns Associated With Insulin Resistance and Type 2 Diabetes Mellitus. Frontiers in Molecular Biosciences 2020;7:609806. doi:10.3389/fmolb.2020.609806. [3]Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 2008;455:1054–6. doi:10.1038/4551054a. Disclosure of Interests None declared